Skip to main content

Table 1 Demographic, clinical, laboratory features and used treatments of patients with systemic lupus erythematosus (n = 84)

From: Association between Staphylococcus aureus nasal carriage and disease phenotype in patients affected by systemic lupus erythematosus

Demographic features Value
 Male/female, n 6/78
 Mean age ± SD (years) 41.3 ± 12.2
 Mean disease duration ± SD (months) 142.1 ± 103.8
Clinical manifestations, n (%)
 Joint involvement 57 (67.8)
 Skin involvement 58 (69.0)
 Serositis 18 (21.4)
 Hematological manifestations 37 (44.0)
 Neuropsychiatric involvement 10 (11.9)
 Renal involvement 31 (36.9)
Laboratory manifestations, n (%)
 Antinuclear antibodies 84 (100.0)
 Anti-DNA 69 (82.1)
 Anti-Sm 13 (15.5)
 Anti-SSA 24 (28.6)
 Anti-SSB 10 (11.9)
 Anti-RNP 10 (11.9)
 Anti-cardiolipin IgG/IgM 30 (35.7)
 Anti-β2Glicoprotein I IgG/IgM 8 (9.5)
 Lupus anticoagulant 12 (14.3)
 Low C3 levels 32 (38.1)
 Low C4 levels 44 (52.4)
Treatments, n (%)
 Corticosteroids 60 (71.4)
 Hydroxychloroquine 54 (64.3)
 Cyclosporine A 19 (22.6)
 Methotrexate 17 (20.2)
 Cyclophosphamide 19 (22.6)
 Mycophenolate mofetil 15 (17.8)
 Azathioprine 18 (21.4)
 ASA 25 (29.7)
 Anticoagulant therapy 9 (10.7)